InfuSystem Announces Distribution Agreement with Genadyne for Negative Pressure Wound Therapy Systems
25 Avril 2023 - 10:30PM
Business Wire
InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or
the “Company”), a leading national health care service provider,
facilitating outpatient care for durable medical equipment
manufacturers and health care providers, announced today a national
distribution agreement with Genadyne Biotechnologies Inc. for its
negative pressure wound therapy (“NPWT”) systems and supplies.
InfuSystem will offer Genadyne’s complete line of wound care
products, including its most advanced XLR8 Plus NPWT Pump, which
delivers advanced variable pressure capabilities with a gradual
wave, in conjunction with Genadyne’s proprietary XLR8 Dressing Kit
with Silver, an antimicrobial contact layer to protect the
wound.
Richard DiIorio, Chief Executive Officer of InfuSystem, said,
“We are pleased to partner with Genadyne in providing our customers
with access to their advanced negative pressure wound therapy
systems and supplies. These products are manufactured in the U.S.
This agreement represents a second NPWT device offering that will
help to mitigate supply chain issues and provide our customers with
multiple options. Our goal through our SI Wound Care partnership is
to provide our patients and partners with a seamless offering of
unique wound care products to promote healing, improve patient
outcomes, and lower the cost of care. We look forward to a long and
mutually beneficial relationship.”
About Genadyne Biotechnologies
At Genadyne, we are focused on creating state-of-the-art
products for advanced wound healing — medical devices and products
that help clinicians provide better care outcomes, speed patients’
healing time, and ultimately improve quality of life. Genadyne
specializes in Negative Pressure Wound Therapy (NPWT) systems and
advanced wound dressings that decrease the risk of pressure ulcer
development. Through continuous research and development, Genadyne
has been able to provide a new dimension to wound care and has been
able to create some of the most advanced, cost-effective products
for the healthcare community. Headquartered in New York, Genadyne
sells its wound care products worldwide in over 55 countries. All
Genadyne products are manufactured and assembled in multiple
manufacturing plants in the U.S., which allows for meticulous
product monitoring and the highest quality assurance in
manufacturing.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading
national health care service provider, facilitating outpatient care
for durable medical equipment manufacturers and health care
providers. INFU services are provided under a two-platform model.
The lead platform is Integrated Therapy Services (“ITS”), providing
the last-mile solution for clinic-to-home healthcare where the
continuing treatment involves complex durable medical equipment and
services. The ITS segment is comprised of Oncology, Pain
Management, Wound Therapy and Lymphedema businesses. The second
platform, Durable Medical Equipment Services (“DME Services”),
supports the ITS platform and leverages strong service orientation
to win incremental business from its direct payer clients. The DME
Services segment is comprised of direct payer rentals, pump and
consumable sales, and biomedical services and repair. Headquartered
in Rochester Hills, Michigan, the Company delivers local,
field-based customer support and also operates Centers of
Excellence in Michigan, Kansas, California, Massachusetts, Texas
and Ontario, Canada.
Forward-Looking Statements
Certain statements contained in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, such as statements
relating to future actions, our share repurchase program and
capital allocation strategy, business plans, growth initiatives,
objectives and prospects, future operating or financial
performance, guidance and expected new business relationships and
the terms thereof. The words “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “expect,”
“strategy,” “future,” “likely,” variations of such words, and other
similar expressions, as they relate to the Company, are intended to
identify forward-looking statements. Forward-looking statements are
subject to factors, risks and uncertainties that could cause actual
results to differ materially, including, but not limited to, our
ability to successfully execute on our growth initiatives, our
ability to enter into definitive agreements for new business
relationships on expected terms or at all, the uncertain impact of
the COVID-19 pandemic, our dependence on estimates of collectible
revenue, potential litigation, changes in third-party reimbursement
processes, changes in law, contributions from acquired businesses
or new business lines, products or services and other risk factors
disclosed in the Company’s most recent annual report on Form 10-K
and, to the extent applicable, quarterly reports on Form 10-Q. All
forward-looking statements made in this press release speak only as
of the date hereof. We do not undertake any obligation to update
any forward-looking statements to reflect future events or
circumstances, except as required by law.
Additional information about InfuSystem Holdings, Inc. is
available at www.infusystem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230425005980/en/
Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC
602-889-9700
InfuSystems (AMEX:INFU)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
InfuSystems (AMEX:INFU)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024